BENEV Exosomes are forging a new standard of care in the medical aesthetic industry. Historically, post-treatment downtime deters many patients from procedures that would otherwise improve their dermal concerns. BENEV Exosomes currently have 6 U.S. patents to their name, as well as 25 clinical studies and counting. In fact, a new study—led by ExoCoBio CEO and CTO, Byong Cho, and BENEV Medical Advisory Board (MAB) member Dr. Diane Duncan, MD, FACS—has just been released.
The latest study, entitled “Development of Exosomes for Esthetic Use,” takes a comprehensive dive into Byong Cho’s passion, inspiration, and ongoing mission to further exosome research for use in the aesthetics industry.
“When used in combination with energy-based device treatment, exosomes reduce inflammation and redness, improve the rapidity of healing for laser and microneedling patients, and reduce the tendency for fibrosis and thick hypertrophic scar formation when used topically.”
Globally, millions of medical and aesthetic providers, along with their patients, trust BENEV Exosomes to effectively shorten treatment downtime, and even revitalize the skin without additional treatment. BENEV Exosomes harness the versatile ability to pair with most routine treatments, and perhaps even the potential to be used with senior patients. Development is still in progress, but Byong Cho is determined: “We need something new—a regenerative esthetics or regenerative medicine treatment option that might be able to reverse certain aspects of aging.”
The first step in developing BENEV Exosomes was using the best formula for a potent product, which Byong Cho believed to be adipose stem cells (ASCE). In 2017, ExoCoBio registered their ASCE-based exosomes with the International Cosmetic Ingredient Dictionary (ICID) of the Personal Care Product Council (PCPC) in the US; “ExoCoBio became the first to have the International Nomenclature Cosmetic Ingredient (INCI) name and, still now, ExoCoBio has proudly the biggest number of exosome registration in the ICID.”
Years of research and development have since been dedicated to ASCE-based exosomes. Just within the last 20 years, the following discoveries have been made.
“Stem cells are live cells, but stem cell–derived exosomes are not live.” Because exosomes are not living cells, the risk for adverse effects (e.g., immune rejection, tumor formation, infection) is low.
ASCE-exosomes are said to harness the best anti-inflammatory effect. According to unpublished ExoCoBio findings, ASCE contains a significant number of miRNA-let-7, one of the most well-known anti-inflammatories.
The overall efficacy of exosomes is significantly different depending on how they are produced. “ExoCoBio has been continuously developing and upgrading the patented ExoSCRT™ technology for mass manufacturing at the highest and consistent quality in compliance with the Good Manufacturing Practice (GMP).”
Moreover, BENEV Exosomes are sourced from ASCE, “the most accessible cell source,” enabling the company to offer affordable, yet still efficacious products.
The medical aesthetic industry is growing rapidly, projected to reach $16.7 billion by 2030. Recent generations such as millennials, Gen Zers, and the in-between zillennials “are increasingly seeking out treatments that can address a variety of skin concerns, including wrinkles, fine lines, sun damage, and loss of volume, without the need for surgery or extensive downtime.” It all comes back to downtime. Some of the most results-driven, clinically proven devices are gathering dust in medical aesthetic practices, as patients prefer to steer clear of excessive pain and downtime!
With the ability to cut downtime in half and even deliver brighter, more youthful-looking skin, providers incorporate EXO Balm, ERC, or ERC+ into their practice and never look back. Dr. Diane Duncan, MAB member and co-researcher in “Development of Exosomes for Esthetic Use,” is an avid BENEV provider. So much so that she developed a take-home version: EXO Balm.
BENEV Exosomes were specially developed with care and a core mission that is still at the forefront of all endeavors. At their root, they are a complete game-changer for most industry treatments, and the drive for better, more effective treatments is apparent.
ASCE-exosome research may never cease, but we are excited to see what’s next for BENEV Exosomes by ExoCoBio.
DISCLAIMER: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.